Introduction. The acute and chronic hepatites remains to be the main problem for the humanity and also for R. Moldova, that´s why the evaluation of drugs with hepatoprotective action is esential, both from a medical and social point of view and also from an economic point of view. Hepatoprotective products are constituents capable of protecting the liver from the destructiv action of endogenous and exogenous factors.  Aim of the study.  Our main goal is to select all the hepatoprotective products that were recorded in R. Moldova, analyzing them according to the State Medicine Nomenclature(SMN).   Materials and methods. For our research, as materials, were used: the SMN that contains 5137 drugs, available on Medicines and Medical Devices Agency (amed.md) and also the scientific literature and guides on the classification of hepatoprotective products.  Results. Hepatoprotective products have a lot of 2.1% of the total number of medicine from the nomenclature (5137), the first in the list are the drugs with vegetal origins: Silymarin products -31, followed by ursodeoxycholic acid products -18, amino acid products -17, phospholipids products -9, and other different groups own an amount of 32 products. At the moment, the following products are absent from the pharmaceutical market: amino acid derivatives: Betaina citrat, Ornitin aspartat; drugs which contain phospholipids: Fosfolip, Lipin, Eplir; drugs with a animal origins: Sirepar, Vitogepat; and also synthetic drugs. According to the pharmaceutical forms, the hepatoprotective can be presented in capsules-55%, followed by tablets-26%, injectable solution-11%, oral solutions-7% and just 1% for vegetal products. We mention that reported to the manufacturing, 43% of hepatoprotective products are produced by EU, and 16% are produced in R. Moldova, etc.  Conclusion. The National Program to combat the viral hepatitis for the years 2017-2021 provides a reduction of 50% till 2021 of the incindence and prevalence for the acute and chronic hepatitis, including through the access of pacients with hepatitis to medical products and to quality treatment services.